Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin

Journal of Cystic Fibrosis

Volumn 10, Issue 2, 2011, Pages 86-92

  Vecellio, Laurent ^a   Abdelrahim, Mohamed E ^b,c   Montharu, Jerome ^b   Galle, Julien ^b   Diot, Patrice ^b   Dubus, Jean Christophe ^d  

^a Aerodrug   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c Beni Suef University   (Egypt)

^d TIMONE HOSPITAL   (France)

Author keywords

Aerosol; Nebulizer; Tobramycin

Indexed keywords

PENTETATE TECHNETIUM TC 99M; TOBRAMYCIN;

ANIMAL EXPERIMENT; ARTICLE; BABOON; COMPARATIVE STUDY; COMPRESSED AIR; CYSTIC FIBROSIS; IN VITRO STUDY; IN VIVO STUDY; NEBULIZER; NONHUMAN; PERFORMANCE; SCINTIGRAPHY;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DATA COLLECTION; EQUIPMENT REUSE; HUMANS; LUNG; MASKS; NEBULIZERS AND VAPORIZERS; PAPIO; PARTICLE SIZE; PNEUMONIA, BACTERIAL; TOBRAMYCIN;

EID: 79952440047     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.10.004     Document Type: Article

References (14)

1. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
2. Boe J., Dennis J.H., O'Driscoll B.R., Bauer T.T., Carone M., Dautzenberg B., et al. European respiratory society guidelines on the use of nebulizers. Eur Respir J 2001, 18:228-242.
3. Dolovich M.B., MacIntyre N.R., Anderson P.J., Camargo C.A., Chew N., Cole C.H., et al. Consensus statement: aerosols and delivery devices. J Aerosol Med 2000, 13:291-300.
4. Heijerman H., Westerman E., Conway S., Touw D., Döring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 2009, 8:295-315. for the consensus working group.
5. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30.
6. Dennis J.H., Pieron C.A. Inhaled antibiotic therapy in evidence: what delivery device?. J Cyst Fibros 2002, 1:209-214.
7. Hubert D., Leroy S., Nove-Josserand R., Murris-Espin M., Mely L., Dominique S., et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009, 8:332-337.
8. Blau H., Mussaffi H., Zahav M.M., Prais D., Livne M., Czitron B.M., et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007, 33:491-495.
9. Martonen T.B., Katz I.M., Musante C.J. A nonhuman primate aerosol deposition model for toxicological and pharmaceutical studies. Inhal Toxicol 2001, 13:307-324.
10. Vecellio L., Grimbert D., Bordenave J., Benoit G., Furet Y., Fauroux B., et al. Residual gravimetric method to measure nebulizer output. J Aerosol Med 2004, 17:63-71.
11. Nikander K., Berg E., Smaldone G.C. Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J Aerosol Med 2007, 20:46-58.
12. Mitchell J.P., Nagel M.W., Nichols S., Nerbrink O. Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006, 19:409-433.
13. Standaert T.A., Vandevanter D., Ramsey B.W., Vasiljev M., Nardella P., Gmur D., et al. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000, 13:147-153.
14. Smith E.C., Denyer J., Kendrick A.H. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995, 8:1214-1221.